Eli Lilly, the American pharmaceutical company, has achieved a significant milestone in the field of oncology with the conditional approval from the European Medicines Agency (EMA) for its drug pirtobrutinib.
This medication, designed as a monotherapy, has been authorized to treat adults facing relapsed or refractory mantle cell lymphoma who have undergone previous treatments.
Pirtobrutinib stands out for being a Bruton tyrosine kinase (BTK) inhibitor with a novel protein binding mechanism, being the first and only reversible BTK inhibitor recognized by the EMA.
The conditional approval is based on the results of a comprehensive phase I and II study, which included the participation of 164 patients across multiple centers.
Mantle cell lymphoma, a rare type of non-Hodgkin lymphoma, represents an important medical challenge, with approximately 200,000 new cases diagnosed worldwide each year.
Eli Lilly's initiative reflects its commitment to research and development of innovative treatments to address unmet medical needs, as highlighted by José Antonio Sacristán, medical director of Lilly Spain.
This achievement comes at a time when Eli Lilly is already experiencing significant financial success. In the first half of the year, the company recorded an impressive 85% increase in its earnings, reaching 1,763 million dollars.
This performance was driven by the success of several medications, including Mounjaro, Verzenio, Jardiance and Taltz. Additionally, the sale of Baqsimi rights contributed 579 million dollars to this growth.
These positive results led the company to revise upward its revenue forecasts for the year, now projecting a range between 33,400 and 33,900 million dollars.
Eli Lilly continues to be a driving force at the intersection of scientific research and medical care, leveraging biotechnology, chemistry and genetics to develop medications that improve people's lives around the world.
This latest advance in oncology reflects the company's commitment to innovation and continuous improvement in medical care.
With information from: PlantaDoce.
Receive all industry news in our weekly Newsletter Dialéctica Científica.